IntroductionAntiplatelet therapy after coronary artery bypass graft (CABG) has been used.
Little is known about the predictors and efficacy of clopidogrel in this
scenario.ObjectiveIdentify predictors of clopidogrel following CABG.MethodsWe evaluated 5404 patients who underwent CABG between 2000 and 2009 at Duke
University Medical Center. We excluded patients undergoing concomitant valve
surgery, those who had postoperative bleeding or death before discharge.
Postoperative clopidogrel was left to the discretion of the attending
physician. Adjusted risk for 1-year mortality was compared between patients
receiving and not receiving clopidogrel during hospitalization after
undergoing CABG.ResultsAt hospital discharge, 931 (17.2%) patients were receiving clopidogrel.
Comparing patients not receiving clopidogrel at discharge, users had more
comorbidities, including hyperlipidemia, hypertension, heart failure,
peripheral arterial disease and cerebrovascular disease. Patients who
received aspirin during hospitalization were less likely to receive
clopidogrel at discharge (P≤0.0001). Clopidogrel was
associated with similar 1-year mortality compared with those who did not use
clopidogrel (4.4% vs. 4.5%, P=0.72). There
was, however, an interaction between the use of cardiopulmonary bypass and
clopidogrel, with lower 1-year mortality in patients undergoing off-pump
CABG who received clopidogrel, but not those undergoing conventional CABG
(2.6% vs 5.6%, P Interaction = 0.032).ConclusionClopidogrel was used in nearly one-fifth of patients after CABG. Its use was
not associated with lower mortality after 1 year in general, but lower
mortality rate in those undergoing off-pump CABG. Randomized clinical trials
are needed to determine the benefit of routine use of clopidogrel in
CABG.